MET and breast carcinoma: One of such potential candidates is c-MET, the product of the proto-oncogene c-MET, overexpression of which has been widely reported in breast cancer, and deregulation of c-MET and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), has been found to promote breast cancer progression and correlates with poor survival[23-25] (also visithttp://www.vai.org/Met/Index.aspx for a comprehensive list of HGF/SF, c-MET and cancer references).